Shield Therapeutics: US commercial update and cash reach extension
Shield Therapeutics PLC (STX) has updated on its commercialisation plan for the US market for its oral treatment Feraccru, (Accrufer in the US) to treat iron deficiency. While the company has engaged with a range of potential commercial partners for Accrufer, it is unlikely to conclude a deal in 2020 as planned, although STX remains confident that there is still room for negotiating on advantageous terms.
STX has moved to provide financial headroom to the end of 2021 via debt financing, initially obtaining c. £4mln from two key shareholders. Its strategic options now include an independent launch in the US facilitated by a lean infrastructure. With a successful market strategy, this could enable STX to recoup substantially greater medium-to-long term returns on Accrufer, in an iron replacement market worth up to US$1bn, than via a profit share or on a royalty basis.
The company is confident that Accrufer’s prospects remain attractive given that it is well-tolerated, has comparable efficacy to standard-of-care, and particularly given that it can be administered safely in a home setting.
Quick facts: Shield Therapeutics PLC
Price: 41 GBX
Market Cap: £48.22 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE